Selected Ongoing Clinical Trials

Breast cancer:

• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292) ClinicalTrials.gov ID NCT04862663¹²
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08) ClinicalTrials.gov ID NCT04556773¹³

Prostate cancer:

• Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280) ClinicalTrials.gov ID NCT05348577¹⁴

Relapsed or Refractory B-cell NHL:

• Study of Capivasertib in Relapsed or Refractory B-cell NHL (CAPITAL) ClinicalTrials.gov ID NCT05008055¹⁵

TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult females with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Data for TRUQAP used to treat this indication are presented elsewhere in this website.

TRUQAP is not indicated to treat other types of breast cancer, nor is it indicated to treat prostate cancer or NHL.